How do you prepare a vasopressin drip, including the volume of diluent?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vasopressin Drip Preparation

Dilute vasopressin 20 units/mL by adding 20 units to 100 mL of normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to create a 0.2 units/mL concentration for intravenous administration. 1

Standard Preparation Protocol

FDA-Approved Dilution Method

  • Add 20 units of vasopressin to 100 mL of diluent (either normal saline or D5W) to achieve a final concentration of 0.2 units/mL 1
  • Alternative concentration: Add 20 units to 200 mL of diluent to create a 0.1 units/mL solution 1
  • For higher volume preparation: Add 25 units to 250 mL of D5W or normal saline to achieve 0.1 units/mL 2

Stability and Storage

  • Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration 1
  • Research demonstrates that vasopressin 0.2 units/mL in normal saline remains stable with less than 10% degradation over 10 days when refrigerated 3

Administration Guidelines

Starting Doses by Indication

  • Post-cardiotomy shock: Start at 0.03 units/minute 1
  • Septic shock: Start at 0.01 units/minute 1, 4
  • Vasodilatory shock (general): 0.01-0.04 units/minute range 4, 5

Titration Protocol

  • Increase by 0.005 units/minute at 10-15 minute intervals until target blood pressure is achieved 1
  • Maximum dose for post-cardiotomy shock: 0.1 units/minute (limited data above this) 1
  • Maximum dose for septic shock: 0.07 units/minute (limited data above this) 1
  • Critical safety threshold: Do not exceed 0.04 units/minute without extreme caution, as doses above this may lead to cardiac arrest 5

Weaning Protocol

  • After target blood pressure maintained for 8 hours without catecholamines, taper by 0.005 units/minute every hour as tolerated 1

Route and Monitoring

Access Requirements

  • Central venous access is strongly preferred to minimize extravasation risk 2
  • Peripheral IV may be used temporarily if central access is unavailable or delayed 2

Monitoring Parameters

  • Monitor blood pressure and heart rate every 5-15 minutes during initial titration 2
  • Target mean arterial pressure (MAP) ≥65 mmHg in vasodilatory shock 2
  • Vasopressin is typically added to norepinephrine therapy rather than used as monotherapy 2

Critical Safety Considerations

Serious Adverse Effects

  • Ischemic complications: skin lesions, digital ischemia, mesenteric ischemia, and coronary ischemia are significant risks 5
  • Decreased cardiac output and bradycardia are common 1
  • Tachyarrhythmias and hyponatremia may occur 1

Contraindications

  • Known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol 1
  • May worsen cardiac function in vulnerable patients 1

Drug Interactions

  • Additive pressor effects with catecholamines - expect enhanced blood pressure response 1
  • Indomethacin may prolong vasopressin effects 1
  • Ganglionic blockers or drugs causing SIADH may increase pressor response 1

Special Clinical Context

Anaphylaxis (Alternative Use)

  • For refractory anaphylaxis not responding to epinephrine and fluids, an alternative 1:100,000 solution can be prepared by adding 1 mg (1 mL) to 100 mL saline, administered at 30-100 mL/h 2

Pediatric Considerations

  • Safety and effectiveness have not been established in pediatric patients 1
  • If used off-label, the "rule of 6" may be applied: 0.6 × body weight (kg) = number of milligrams diluted to 100 mL saline; then 1 mL/h delivers 0.1 mcg/kg/min 2

References

Guideline

Vasopressin Infusion Preparation Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Extended stability of vasopressin 0.2 unit/mL in PVC containers.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.